PharmacoEconomics & Outcomes News 710, p4 - 30 Aug 2014 HCV treatment recommendations now include prioritising patients The US hepatitis C virus (HCV) guideline website, HCVguidelines.org, has a new section on the prioritisation of patients according to those who will derive the most benefit or will have the greatest impact on limiting further HCV transmission. The latest section of the website – a collaboration between the AASLD, the IDSA and the IAS-USA* – was developed by a panel of 27 specialists and a patient advocate, and provides recommendations based on the latest evidence and panel consensus. They include giving highest priority to patients with advanced fibrosis with compensated cirrhosis and liver transplant recipients, and high priority given to patients at high risk for liver-related complications and severe extra-hepatic HCV complications. The website will be updated regularly to keep pace with improved and emerging diagnostic tools and new drug options. President of IDSA, Dr Barbara Murray, says "this new guidance will help clinicians determine the best course of therapy for each patient given their unique condition". The three organisations will continue their collaboration, with the next two sections already underway; they will address monitoring treated patients and management of acute HCV infection. * American Association for the Study of Liver Disease (AASLD); Infectious Diseases Society of America (IDSA); International Antiviral Society (IAS)-USA Infectious Diseases Society of America, et al. HCV Treatment Recommendations Now Includes Information on Prioritizing Patients Under Limited Resources. Media Release : 11 Aug 2014. Available from: URL: http:// 809167036 www.hcvguidelines.org

1173-5503/14/0710-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved

PharmacoEconomics & Outcomes News 30 Aug 2014 No. 710

1